[go: up one dir, main page]

WO2008033368A3 - Boroproline compound and cytokine combination therapy - Google Patents

Boroproline compound and cytokine combination therapy Download PDF

Info

Publication number
WO2008033368A3
WO2008033368A3 PCT/US2007/019767 US2007019767W WO2008033368A3 WO 2008033368 A3 WO2008033368 A3 WO 2008033368A3 US 2007019767 W US2007019767 W US 2007019767W WO 2008033368 A3 WO2008033368 A3 WO 2008033368A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
cytokine combination
boroproline
boroproline compound
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019767
Other languages
French (fr)
Other versions
WO2008033368A2 (en
Inventor
Nazneen Aziz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dara Biosciences Inc
Original Assignee
Dara Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences Inc filed Critical Dara Biosciences Inc
Publication of WO2008033368A2 publication Critical patent/WO2008033368A2/en
Anticipated expiration legal-status Critical
Publication of WO2008033368A3 publication Critical patent/WO2008033368A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method is provided for treating subjects with boroproline compound and cytokine combination therapy. The invention further provides methods for identifying subjects that are likely to respond to boroproline treatment.
PCT/US2007/019767 2006-09-12 2007-09-12 Boroproline compound and cytokine combination therapy Ceased WO2008033368A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84385406P 2006-09-12 2006-09-12
US60/843,854 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033368A2 WO2008033368A2 (en) 2008-03-20
WO2008033368A3 true WO2008033368A3 (en) 2009-05-07

Family

ID=39184306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019767 Ceased WO2008033368A2 (en) 2006-09-12 2007-09-12 Boroproline compound and cytokine combination therapy

Country Status (1)

Country Link
WO (1) WO2008033368A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
WO2020123496A1 (en) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077601A1 (en) * 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077601A1 (en) * 2002-07-09 2004-04-22 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds

Also Published As

Publication number Publication date
WO2008033368A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
WO2010019271A8 (en) Fluorescent regulators of rassf1a expression and human cancer cell proliferation
WO2009074968A3 (en) Method for predicting the efficacy of cancer therapy
EP2097012A4 (en) Devices and methods for the treatment of heart failure
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
EP1786515A4 (en) Treatment of the autonomic nervous system
EP1906854A4 (en) Medical-treatment electrode assembly and method for medical treatment
ZA200904519B (en) Emission treatment systems and methods
IL183059A0 (en) Cancer treatment method
GB0604471D0 (en) Device and method for the treatment of tumours
EP1755394A4 (en) Cancer treatment method
WO2008155390A3 (en) Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
IL179323A0 (en) Cancer treatment method
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
WO2009105507A3 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
WO2007058957A3 (en) Boroproline compound and cytokine combination therapy
IL226362A0 (en) Compounds, and methods for the treatment of cancer
IL179359A0 (en) Cancer treatment method
EP1802617A4 (en) Cancer treatment method
WO2008092103A3 (en) Combination cancer treatments comprising elsamitrucin and other agents
HK1131409A (en) For the identification, assessment, and treatment of patients with cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838048

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838048

Country of ref document: EP

Kind code of ref document: A2